Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANYSE:AMAMNASDAQ:KRYSNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$21.20-10.2%$20.06$6.84▼$25.67$5.04B0.573.75 million shs14.14 million shsAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/AKRYSKrystal Biotech$137.60+0.6%$173.11$132.47▼$219.34$3.98B0.79299,448 shs534,868 shsRVMDRevolution Medicines$42.01+11.6%$37.23$29.17▼$62.40$7.83B1.111.49 million shs6.59 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+1.95%-0.85%+28.25%+39.47%+241.51%AMAMAmbrx Biopharma0.00%0.00%0.00%0.00%0.00%KRYSKrystal Biotech-1.91%-19.47%-17.60%-15.06%-15.43%RVMDRevolution Medicines+0.59%-6.74%+19.94%-13.56%-3.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.2749 of 5 stars2.61.00.00.03.81.71.9AMAMAmbrx BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.8976 of 5 stars4.53.00.04.72.43.31.9RVMDRevolution Medicines4.3276 of 5 stars4.50.00.04.73.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2514.39% UpsideAMAMAmbrx Biopharma 0.00N/AN/AN/AKRYSKrystal Biotech 3.00Buy$218.6358.88% UpsideRVMDRevolution Medicines 3.00Buy$67.1759.87% UpsideCurrent Analyst Ratings BreakdownLatest AMAM, RVMD, ADMA, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M11.81$0.07 per share311.70$0.60 per share35.33AMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18KRYSKrystal Biotech$333.45M11.93$3.49 per share39.38$32.85 per share4.19RVMDRevolution Medicines$742K10,546.40N/AN/A$11.09 per share3.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8275.7130.72N/A17.80%53.20%26.07%N/AAMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/AKRYSKrystal Biotech$10.93M$4.1646.0213.65N/A30.69%11.41%10.40%N/ARVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%N/ALatest AMAM, RVMD, ADMA, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26AMAMAmbrx BiopharmaN/A13.2813.28KRYSKrystal BiotechN/A7.287.76RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AMAMAmbrx Biopharma77.28%KRYSKrystal Biotech86.29%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AMAMAmbrx Biopharma0.64%KRYSKrystal Biotech13.70%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530237.62 million227.64 millionOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableRVMDRevolution Medicines250186.26 million154.76 millionOptionableAMAM, RVMD, ADMA, and KRYS HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. (NASDAQ:RVMD) Holdings Cut by Casdin Capital LLCMay 8 at 7:13 AM | marketbeat.comRevolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call TranscriptMay 7 at 7:03 PM | seekingalpha.comRevolution Medicines, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7 at 6:59 PM | seekingalpha.comRevolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate ProgressMay 7 at 4:02 PM | globenewswire.comBalyasny Asset Management L.P. Sells 348,957 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 7 at 6:15 AM | marketbeat.comThe Manufacturers Life Insurance Company Buys 24,698 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 7 at 4:36 AM | marketbeat.comAvidity Partners Management LP Reduces Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 7:39 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Holdings Boosted by Baker BROS. Advisors LPMay 6 at 7:39 AM | marketbeat.comBVF Inc. IL Acquires 702,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 7:30 AM | marketbeat.comBellevue Group AG Cuts Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 6:32 AM | marketbeat.comBoxer Capital Management LLC Buys Shares of 4,279,464 Revolution Medicines, Inc. (NASDAQ:RVMD)May 4, 2025 | marketbeat.comRevolution Medicines (RVMD) Projected to Post Quarterly Earnings on WednesdayMay 4, 2025 | marketbeat.comFirst Trust Advisors LP Sells 35,269 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 3, 2025 | marketbeat.comRevolution Medicines (RVMD) Expected to Announce Quarterly Earnings on WednesdayMay 2, 2025 | americanbankingnews.comRevolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025April 30, 2025 | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Shares Up 5.8% - Should You Buy?April 30, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given "Outperform" Rating at WedbushApril 30, 2025 | marketbeat.comHsbc Holdings PLC Trims Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 30, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Revolution Medicines (NASDAQ:RVMD)April 30, 2025 | americanbankingnews.comArtia Global Partners LP Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29, 2025 | marketbeat.comWhy Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.47%April 29, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketAMAM, RVMD, ADMA, and KRYS Company DescriptionsADMA Biologics NASDAQ:ADMA$21.20 -2.41 (-10.21%) Closing price 04:00 PM EasternExtended Trading$21.40 +0.20 (+0.94%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Ambrx Biopharma NYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$137.60 +0.80 (+0.59%) Closing price 03:59 PM EasternExtended Trading$137.17 -0.43 (-0.31%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Revolution Medicines NASDAQ:RVMD$42.01 +4.35 (+11.56%) Closing price 03:59 PM EasternExtended Trading$41.91 -0.10 (-0.25%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
